Qilu Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Drug: Voclosporin（QL1074）Drug: Placebo
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT06406205
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- Conditions
- Colorectal CancerPancreatic CancerNon-small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06403735
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳Harbin Medical university cancer hospital, Ha'erbin, Heilongjiang, China
🇨🇳Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06394713
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT06371534
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06261359
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: The reference octreotide microsphereDrug: The test octreotide microsphere
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06254235
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06232902
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06173011
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
- Conditions
- Myopia
- Interventions
- Drug: QLM3004 Concentration 1Drug: QLM3004 Concentration 2Drug: QLM3004 Concentration 3Other: Placebo
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 735
- Registration Number
- NCT06151587
- Locations
- 🇨🇳
The Affiliated Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vehicle (Placebo)Drug: 1.5% QLM3003Drug: 2% QLM3003
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06058000
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Dermatology Hospital of Shandong First Medical University, Jinan, Shandong, China